1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Suven Pharmaceuticals Limited

Suven Pharmaceuticals Limited

SUVENPHAR.BO
Suven Pharmaceuticals LimitedIN flagBombay Stock Exchange
1,075.30
INR
- -
- -
411.37BMarket Cap
Suven Pharmaceuticals Limited
SUVENPHAR.BO
(Bombay Stock Exchange)

Recent

price

1,075.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
FRC
14.52
32.1
39.1
51.34
52.29
41.31
47.58
47.13
Revenue per Share
4.29
12.45
14.23
17.83
16.16
11.8
10.52
10.41
Basic EPS, GAAP
-0.25
11.94
10.67
10.01
6.73
13.08
5.26
- -
Free Cash Flow per Basic Share
0.9
3.01
1
4
8
- -
- -
- -
Dividend per Share
15.86
24.68
37.79
51
58.56
70.36
1.01
1
Book Value per Share
23.08
33.07
46.28
59.9
65.72
78.15
44.57
44.14
Tangible Book Value per Share
255
255
255
255
255
254
252
254
Basic Weighted Avg Shares
3,696
8,173
9,955
13,070
13,311
10,514
11,976
11,976
Sales/Revenue/Turnover
44.1
44.22
41.32
41.56
39.54
33.41
24.86
24.86
Operating Margin (%)
115
237
312
383
465
546
775
775
Depreciation Expense
1,093
3,170
3,623
4,538
4,113
3,003
2,648
2,645
Net Income, GAAP
30.78
21.63
22.52
32.02
26.52
25.98
23.01
23.01
Effective Tax Rate (%)
29.57
38.79
36.4
34.72
30.9
28.56
22.11
22.09
Profit Margin (%)
2,321
1,913
3,450
9,176
8,523
11,563
5,234
5,234
Working Capital
- -
918
363
289
53
212
1,757
1,757
LT Debt
5,903
8,448
11,808
15,272
17,352
20,507
18,406
18,406
Total Equity
- -
33.14
27.01
25.02
22.52
13.26
10.82
10.82
Return on Invested Capital (%)
- -
51.14
38.49
36.64
28.46
17.9
23.81
23.75
Return on Capital (%)
- -
61.44
45.57
40.16
29.5
18.3
29.16
29.13
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'25
ST Debt
88
- -
1,033
LT Borrowings
71
- -
62
LT Finance Leases
235
- -
1,695
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
255
- -
255
Market Capitalization
298,090
288,661
294,709

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'25
Total Current Assets
11,676
- -
8,886
Cash, Cash Equivalents & STI
6,730
- -
2,904
Accounts Receivable, Net
1,840
- -
2,844
Inventories
2,155
- -
1,666
Total Current Liabilities
2,381
- -
3,652
Payables & Accruals
- -
- -
- -
ST Debt
88
- -
1,033
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
18.13%
-10.24%
Free Cash Flow
- -
-3.09%
-60.21%
Net Income, GAAP
- -
-1.73%
-11.83%
Sales/Revenue/Turnover
- -
9.57%
13.91%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
3,388
2,784
3,538
3,601
13,311
2024
3,476
2,310
2,198
2,374
10,514
2025
2,307
2,577
3,072
4,020
11,976

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
4.22
2.83
4.23
- -
16.16
2024
4.74
3.12
1.84
- -
11.8
2025
2.39
3.23
3.26
- -
10.52

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
8
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Venture Life Group plc (VLG.L)
MGC Pharmaceuticals Limited (MGCLF)
BIGtoken, Inc. (FPVD)
InnoPharmax Inc. (4172.TWO)
Teva Pharmaceutical Industries Limited (TEVJF)
Eris Lifesciences Limited (ERIS.NS)
Business
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) operates as an integrated technology-driven contract development and manufacturing organization (CDMO) platform serving global pharmaceutical and biotech companies; it specializes in custom synthesis, process research and development, scale-up manufacturing, analytical services, formulation development, clinical supplies manufacturing and packaging, and regulatory support for new chemical entities, intermediates, active pharmaceutical ingredients, and formulations. The company delivers comprehensive analytical chemistry capabilities encompassing method development and validation using HPLC and GC/GC-HS, structure elucidation by NMR, LC-MS/MS analysis, DSC and TGA testing, chiral and HPLC purity assessments, organic volatile impurities and residual solvents detection, ICH-compliant stability studies, impurity profiling, and achiral/chiral separations. Cohance Lifesciences maintains operations primarily in India with headquarters in Hyderabad, Telangana, and extends its reach through strategic global partnerships, targeting healthcare customers in drug discovery, development, and commercialization across regions including North America. Incorporated in 2018 as a demerger from Suven Life Sciences Limited, the company underwent a major acquisition by Advent International, which secured a controlling stake in 2024 followed by debt financing for further consolidation; it completed a 56% equity acquisition in NJ Bio Inc. for $64.4 million on December 28, 2024, including a $15 million primary infusion to bolster biopharmaceutical capabilities in antibody-drug conjugates (ADCs) and targeted therapeutics manufacturing in Princeton, New Jersey. In May 2025, the company changed its name to Cohance Lifesciences Limited and updated its stock symbol to COHANCE from SUVENPHAR on the National Stock Exchange, reflecting a merger with Advent's portfolio entity Cohance Lifesciences to form a billion-dollar platform focused on APIs and advanced CDMO services; recent developments also include a successful USFDA audit in March 2025 and ongoing expansions in ESG infrastructure, R&D technology platforms, and customer collaborations.